Martin Schwalm

Mr. Martin Schwalm

EUbOPEN
+2
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2023 in Cell Chemical Biology
Verified
Journal Article
Closed access
MSMartin Schwalm
Martin Schwalm
AKAndreas Krämer
Andreas Krämer
ADAnja Dölle
Anja Dölle
JWJanik Weckesser
Janik Weckesser
XYXufen Yu
Xufen Yu
SKStefan Knapp
Stefan Knapp

25 August 2022 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
VNVáclav Němec
Václav Němec
MSMartin Schwalm
Martin Schwalm
SMSusanne Müller
Susanne Müller
SKStefan Knapp
Stefan Knapp
Small molecule degraders such as PROTACs (PROteolysis TArgeting Chimeras) have emerged as new promising pharmacological modalities and the first PROTAC drug candidates are now studied clinically. The catalytic properties of PROTACs, acting as chemical degraders of a protein of interest (POI), represent an attractive new strategy for drug development. The development and characterization of PROTACs requires an array of additional assay systems that track the degradation pathway leading ultimately to degradation of the POI, identifying critical steps for PROTAC optimization. In addition to their exciting translational potential, PROTACs represent versatile chemical tools that considerably expanded our chemical biology toolbox and significantly enlarged the proteome that can be modulated by small molecules. Similar to conventional chemical probes, PROTACs used as chemical probes in target validation require comprehensive characterization. As a consequence, PROTAC-specific quality criteria should be defined by the chemical biology community. These criteria need to comprise additional or alternative parameters compared to those for conventional occupancy-driven chemical probes, such as the maximum level of target degradation (Dmax), confirmation of a proteasome dependent degradation mechanism and, importantly, also kinetic parameters of POI degradation. The kinetic aspects are particularly relevant for PROTACs that harbor covalent binding moieties. Here, we review recent progress in the development of assay systems for PROTAC characterization and suggest a set of criteria for PROTACs as high quality chemical probes.

21 May 2024 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DODominic D. G. Owens
Dominic D. G. Owens
MMMatthew E. R. Maitland
Matthew E. R. Maitland
AYAliakbar Khalili Yazdi
Aliakbar Khalili Yazdi
XSXiaosheng Song
Xiaosheng Song
VRViviane Reber
Viviane Reber
CACheryl H. Arrowsmith
Cheryl H. Arrowsmith


6 June 2025 in Science Advances
Verified
Journal Article
Open access
NRNicolai D. Raig
Nicolai D. Raig
KSKatherine J. Surridge
Katherine J. Surridge
MSMarta Sanz-Murillo
Marta Sanz-Murillo
VDVerena Dederer
Verena Dederer
AKAndreas Krämer
Andreas Krämer
SKStefan Knapp
Stefan Knapp
Increased kinase activity of leucine-rich repeat kinase 2 (LRRK2) is associated with Parkinson’s disease (PD). Numerous LRRK2-selective type I kinase inhibitors have been developed, and some have entered clinical trials. Here, to our knowledge, we present the first type II kinase inhibitors that target LRRK2. Targeting the inactive conformation of LRRK2 is functionally distinct from targeting the active-like conformation using type I inhibitors. We designed these inhibitors with a combinatorial chemistry approach fusing selective LRRK2 type I and promiscuous type II inhibitors using iterative cycles of synthesis supported by structural biology and activity testing. Our lead compounds are selective and potent toward both LRRK2 and LRRK1, a close relative of LRRK2. Through cellular assays, cryo–electron microscopy structural analysis, and in vitro motility assays, we show that our inhibitors stabilize the open, inactive LRRK2 kinase conformation. These new conformation-specific compounds will be invaluable as tools to study LRRK2’s function and regulation and expand the potential therapeutic options for PD.

5 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JDJohannes Dopfer
Johannes Dopfer
JVJames D. Vasta
James D. Vasta
SMSusanne Müller
Susanne Müller
SKStefan Knapp
Stefan Knapp
MRMatthew B. Robers
Matthew B. Robers
MSMartin Schwalm
Martin Schwalm
Investigating ligand-protein complexes is essential in the areas of chemical biology and drug discovery. However, detailed information on key reagents such as fluorescent tracers and associated data for the development of widely used bioluminescence resonance energy transfer (BRET) assays including NanoBRET, time-resolved Förster resonance energy transfer (TR-FRET) and fluorescence polarization (FP) assays are not easily accessible to the research community. We created tracerDB, a curated database of validated tracers. This resource provides an open access knowledge base and a unified system for tracer and assay validation. The database is freely available at https://www.tracerdb.org/.